| Literature DB >> 30523328 |
Guy Ledergor1,2, Assaf Weiner1, Mor Zada1, Shuang-Yin Wang1, Yael C Cohen3,4, Moshe E Gatt5,6, Nimrod Snir4,7, Hila Magen4,8, Maya Koren-Michowitz4,9, Katrin Herzog-Tzarfati4,9, Hadas Keren-Shaul1,10, Chamutal Bornstein1, Ron Rotkopf10, Ido Yofe1, Eyal David1, Venkata Yellapantula11,12, Sigalit Kay3, Moshe Salai4,7, Dina Ben Yehuda5,6, Arnon Nagler4,8, Lev Shvidel6,13, Avi Orr-Urtreger4,14, Keren Bahar Halpern15, Shalev Itzkovitz15, Ola Landgren16, Jesus San-Miguel17, Bruno Paiva17, Jonathan J Keats18, Elli Papaemmanuil12, Irit Avivi3,4, Gabriel I Barbash19, Amos Tanay20,21, Ido Amit22.
Abstract
Multiple myeloma, a plasma cell malignancy, is the second most common blood cancer. Despite extensive research, disease heterogeneity is poorly characterized, hampering efforts for early diagnosis and improved treatments. Here, we apply single cell RNA sequencing to study the heterogeneity of 40 individuals along the multiple myeloma progression spectrum, including 11 healthy controls, demonstrating high interindividual variability that can be explained by expression of known multiple myeloma drivers and additional putative factors. We identify extensive subclonal structures for 10 of 29 individuals with multiple myeloma. In asymptomatic individuals with early disease and in those with minimal residual disease post-treatment, we detect rare tumor plasma cells with molecular characteristics similar to those of active myeloma, with possible implications for personalized therapies. Single cell analysis of rare circulating tumor cells allows for accurate liquid biopsy and detection of malignant plasma cells, which reflect bone marrow disease. Our work establishes single cell RNA sequencing for dissecting blood malignancies and devising detailed molecular characterization of tumor cells in symptomatic and asymptomatic patients.Entities:
Mesh:
Year: 2018 PMID: 30523328 DOI: 10.1038/s41591-018-0269-2
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440